Clinical trials: Familial Alzheimer Disease (FAD)
Alzheimer Disease, Familial Alzheimer Disease (FAD)
The Chinese Familial Alzheimer's Network
This research will establish and continuously improve the FAD research network in conjunction with multi-center institutions nationwide.
- Trial name
- CFAN (NCT03657732)
- Where
- 65 sites in China
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Capital Medical University
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
China HEalthy Aging and Dementia Study (HEAD)
The China HEalthy Aging and Dementia (HEAD) study is a large-scale, community-based, multi-center prospective cohort study covering eastern, northern, southern, and central-western regions of China.
- Conditions
- Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), Dementia, Vascular Dementia (VaD)
- Trial name
- NCT07912710
- Where
- 30 sites in China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Fudan University
Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset
China Cognition and Aging Study
The aim of this study is to establish and perfect the China Cognition and Aging Study (China COAST) cohort, to clarify the epidemiology, influencing factors, genetic characteristics, pathogenesis, disease characteristics and…
- Conditions
- Mild Cognitive Impairment(MCI), Alzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Vascular Dementia (VaD)
- Trial name
- COAST (NCT03653156)
- Where
- 65 sites in China
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Capital Medical University
Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
The study will be conducted in 2 blinded parts (Part 1 and Part 2). In Part 1, study participants who are mutation carriers will receive active donanemab and non-mutation carriers will receive placebo-donanemab for up to 18…
- Conditions
- Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease, Alzheimers Disease
- Trial name
- NCT06996730
- Testing
- Donanemab, RG6289
- Where
- Colombia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Banner Health